Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bjid.2020.06.005 http://scihub22266oqcxt.onion/10.1016/j.bjid.2020.06.005 32603679!7320855!32603679     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Braz+J+Infect+Dis 2020 ; 24 (4): 365-367 Nephropedia Template TP {{tp|p=32603679|t=2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?|pdf=|usr=}}{{32603679}} gab.com Text Calcineurin inhibitors revisited: A new paradigm for COVID-19 JO: Braz J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32603679 #FOAvip The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19. Twit Text FOAVip Calcineurin inhibitors revisited: A new paradigm for COVID-19 ????Braz J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32603679 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32603679 #FOAvip English Wikipedia <ref>{{Cite pmid|32603679}}</ref> Calcineurin inhibitors revisited: A new paradigm for COVID-19? #MMPMID32603679 Hage R; Steinack C; Schuurmans MM Braz J Infect Dis 2020[Jul]; 24 (4): 365-367 PMID32603679show ga The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19. |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Calcineurin Inhibitors/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH]Calcineurin inhibitors revisited: A new paradigm for COVID-19?(epmc).pdf DeepDyve Pubget Overpricing